In atherosclerosis and NASH, pneumococcal immunization has been shown to ameliorate inflammation and disease severity (18, 20, 31), suggesting that this treatment may be beneficial to the systemic components of NPC1. Here, NPC1 is linked to metabolic dysfunction-associated steatohepatitis.